Name: Latest research reports of Gland Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Gland Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Gland Pharma Ltd.

NSE: GLAND | BSE: 543245 | ISIN: INE068V01023 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive

2022.8000 6.30 (0.31%)

NSE Sep 19, 2025 15:31 PM

58.30% Gain from 52W Low

Volume: 176.3K

Gland Pharma Ltd.

06 Aug 2025

2022.80

0.31%

Strong margin gain boosts PAT by 50% YoY

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) posted revenue in line with our estimate in 1QFY26. However, EBITDA/PAT exceeded our estimates (13%/16% beat).

Gland Pharma Ltd. has an average target of 2145.00 from 2 brokers.